Pharmacological Study of IQM-97,423, a Potent and Selective CCK1 Receptor Antagonist with Protective Effect in Experimental Acute Pancreatitis

The pharmacological profile of the new CCK 1 receptor antagonist IQM-97,423, (4aS,5R)-2-benzyl-5-(tert-butylaminocarbonyl-tryptophyl)amino-1,3-dioxoperhydropyrido-[1,2-c]pyrimidine, was examined in in vitro and in vivo studies and compared with typical CCK 1 antagonists such as devazepide and lorglu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacology 2004-01, Vol.72 (2), p.68-76
Hauptverfasser:	Latorre, M., Bartolomé-Nebreda, J.M., García-López, M.T., González-Muñiz, R., Herranz, R., Del Río, J., Cenarruzabeitia, E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease alpha-Amylases - antagonists & inhibitors alpha-Amylases - biosynthesis Animals Binding, Competitive Cerebral Cortex - metabolism Cholecystokinin - pharmacology Devazepide - pharmacology Disease Models, Animal Guinea Pigs Ileum - innervation In Vitro Techniques Male Mice Muscle Contraction - drug effects Muscle, Smooth - innervation Myenteric Plexus Neuromuscular Junction - drug effects Neuromuscular Junction - physiology Original Paper Pancreatitis - chemically induced Pancreatitis - drug therapy Peptide Fragments - pharmacology Proglumide - analogs & derivatives Proglumide - pharmacology Pyrimidinones - pharmacology Rats Rats, Wistar Receptor, Cholecystokinin A - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!